ClinicalTrials.gg
RecruitingNCT07633639Updated Jun 8, 2026

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

An interventional study of LSG-Semaglutide group and LSG-Mazdutide group in Obesity, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Obesity by China-Japan Friendship Hospital — 8 open to participants now, 8 under way, none of them phase 3. Obesity · China-Japan Friendship Hospital.

Started
2026
the only one that year
No phase
4 of 10
4 open now
Registered
9th of 10
by date

Among the 10 studies in Obesity by China-Japan Friendship Hospital, this one is the only one that started in 2026, is one of 4 with no phase, and was the 9th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 10 studies in Obesity by China-Japan Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by China-Japan Friendship Hospital, or all of them as a file.
02

Study summary

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.

Read the detailed description

Bariatric surgery is guideline-recommended as an effective obesity treatment. Substantial evidence demonstrates its ability to significantly reduce weight, improve comorbidities like type 2 diabetes (T2DM) and dyslipidemia, and lower cardiovascular risk. However, the significant heterogeneity and complex comorbidity profiles among obese patients challenge long-term effective management with single therapeutic approaches. While currently the most effective weight-loss intervention, bariatric surgery requires attention to issues such as postoperative weight regain and metabolic deterioration.

In parallel, glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated significant efficacy in obesity management. Agents like Semaglutide promote weight loss and metabolic improvement through mechanisms including insulin secretion promotion, appetite suppression, delayed gastric emptying, and enhanced satiety. Tirzepatide, as the first approved GLP-1/GIP dual-target agonist, demonstrates superior hypoglycemic and weight loss effects compared to Semaglutide through its synergistic interaction with GLP-1. Mazdutide, the first GLP-1/GCG dual-target agonist to enter phase III clinical trials in China, promotes fatty acid oxidation and energy consumption while acting synergistically with GLP-1's appetite-suppressing effect. It can effectively reduce liver fat content while achieving weight loss.

Given the distinct advantages of both bariatric surgery and GLP-1RA therapy in weight and metabolic control, this study will combine these modalities into a comprehensive treatment strategy. We will compare the long-term safety and effectiveness of different combination regimens for weight management and metabolic improvement in Chinese patients with obesity.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • obesity
  • Glucagon-Like Peptide-1 Receptor Agonists
  • Metabolic Bariatric Surgery
  • Semaglutide
  • Mazdutide
  • Tirzepatide
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).
  2. obesity: ≥30 kg/m².
  3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
  4. Age range: 18-60 years (inclusive).
  5. : Willing participation with documented consent.

Exclusion criteria

Exclusion Criteria:

  1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.
  2. Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.
  3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).
  4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications.
  5. Significant comorbidities:

5.1Advanced hepatic/renal dysfunction ( C or \<30 mL/min/1.73m²). 5.2Active (except non-melanoma skin cancers). 5.3Autoimmune disorders requiring . 5.4Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression).

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    LSG-Semaglutide group

    Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: Semaglutide. Dosage:The starting dose was 0.25 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 2.4 mg per week. Frequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.

    Combination Product: LSG-Semaglutide group

  • Experimental
    LSG-Mazdutide group

    Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs:Mazdutide. Dosage:The starting dose was 2 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 6 mg per week. Frequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.

    Combination Product: LSG-Mazdutide group

  • Experimental
    LSG-Tirzepatide group

    Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs:Tirzepatide. Dosage:The starting dose was 2.5 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 10 mg per week. Frequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.

    Combination Product: LSG-Tirzepatide group

  • Other
    LSG group

    Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: N/A. Observation Group: Received only basic nutritional recommendation interventions after surgery.

    Procedure: LSG group

Interventions

  • Combination productLSG-Semaglutide group

    1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal/day). From 30 to 90 days post-surgery, a low-energy diet (400 kcal/day) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal/day for men and 1,200 kcal/day for women). 2. In addition to laparoscopic sleeve gastrectomy and postoperative basic nutritional counseling,the LSG-Semaglutide group received subcutaneous semaglutide injections from 1 to 6 months postoperatively.The specific protocol was as follows:In the intervention group, semaglutide treatment was initiated at 1 month after LSG. The starting dose was 0.25 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 2.4 mg per week. The treatment continued until the completion of the 6-month postoperative period.

  • Combination productLSG-Mazdutide group

    1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal/day). From 30 to 90 days post-surgery, a low-energy diet (400 kcal/day) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal/day for men and 1,200 kcal/day for women). 2. In addition to laparoscopic sleeve gastrectomy and postoperative basic nutritional counseling,the LSG-Mazdutide group received subcutaneous Mazdutide injections from 1 to 6 months postoperatively.The specific protocol was as follows:In the intervention group, Mazdutide treatment was initiated at 1 month after LSG. The starting dose was 2 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 6 mg per week. The treatment continued until the completion of the 6-month postoperative period.

  • Combination productLSG-Tirzepatide group

    1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal/day). From 30 to 90 days post-surgery, a low-energy diet (400 kcal/day) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal/day for men and 1,200 kcal/day for women). 2. In addition to laparoscopic sleeve gastrectomy and postoperative basic nutritional counseling,the LSG-Tirzepatide group received subcutaneous Tirzepatide injections from 1 to 6 months postoperatively.The specific protocol was as follows:In the intervention group, Tirzepatide treatment was initiated at 1 month after LSG. The starting dose was 2.5 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 10 mg per week. The treatment continued until the completion of the 6-month postoperative period.

  • ProcedureLSG group

    1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal/day). From 30 to 90 days post-surgery, a low-energy diet (400 kcal/day) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal/day for men and 1,200 kcal/day for women). 2. Observation Group: Received only basic nutritional recommendation interventions after surgery.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., MazdutideStudies of MazdutideMazdutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Percentage of weight loss.

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

Secondary outcomes

  1. Weight in kilograms

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  2. Waist circumference in centimeters

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  3. Hip circumference in centimeters

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  4. Blood pressure

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  5. Serum creatinine

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  6. Glomerular filtration rate

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  7. Fasting blood glucose

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  8. Average blood glucose from continuous glucose monitoring

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  9. Postprandial 2-hour blood glucose

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  10. HbA1c

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  11. Urinary microalbumin

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  12. Total cholesterol

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  13. Low-Density Lipoprotein(LDL)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  14. Triglycerides

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  15. Alanine Aminotransferase(ALT)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  16. Aspartate Aminotransferase(AST)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  17. urine microalbumin-to-creatinine ratio (ACR)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  18. uric acid(UA)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  19. body fat percentage(BFP)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  20. Visceral fat area

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  21. Muscle mass in kilograms

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  22. Body fat percentage

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  23. lean body mass (LBM)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  24. lean body mass percentage (LBMP)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  25. Liver Stiffness Measurement(LSM)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

  26. Controlled Attenuation Parameter(CAP)

    Time frame: Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 8, 2026
StartActual
May 1, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2028
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07633639
Responsible party
Hua Meng (Prof., China-Japan Friendship Hospital) — Principal investigator
First posted
Jun 8, 2026
Start date
May 1, 2026
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Jun 8, 2026

Study contacts

Yishan Huang, Ph.D
Contact
yuanwen0920@163.com
+8618612256920

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Semaglutide · Tirzepatide · Mazdutide

Start the discussion